3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
6
Phase 3
2
Status
Terminated
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
13
Lymphoma, Follicular
3
Waldenstrom Macroglobulinemia
2
Lymphoma, Non-Hodgkin
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia
2
Lymphoma, B-Cell
1
Lymphoma
1
Hematologic Diseases
1
Interventions
ibrutinib
4
Rituximab
4
fludarabine phosphate
3
Peripheral Blood Stem Cell Transplantation
3
liposomal amphotericin B
2
idelalisib
2
Whole-Body Irradiation
2
Mycophenolic Acid
2
Epoetin Alfa
2
Early Intervention, Educational
2
Darbepoetin alfa
2
Cyclosporins
2
Cyclosporine
2
Chlorambucil
2
zanubrutinib
1
fludarabine
1
ferrous sulfate
1
ferric gluconate
1
Vancomycin
1
Tazobactam
1
Sucrose
1
Sirolimus
1
Psychiatric Rehabilitation
1
Piperacillin, Tazobactam Drug Combination
1
Piperacillin
1
Pharmacogenomic Testing
1
Ondansetron
1
Morphine
1
Ketamine
1
Interferon-alpha
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Waldenstrom Macroglobulinemia
×
idelalisib
×
Clear all
NCT01732913
2018-11-16
Yosemite
Gilead Sciences
Phase 3
Terminated
295 enrolled
9 charts
NCT01732926
2018-11-16
Bridalveil
Gilead Sciences
Phase 3
Terminated
475 enrolled
9 charts